Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
This Medical Crossfire® filmed panel discussion aims to ensure the knowledge and ability of oncology healthcare professionals to apply evidence on immuno-oncology strategies and emerging biomarker information that can assist them to personalize care for their patients with advanced NSCLC. Medical Crossfire® brings together internationally known experts for guidance, interpretation and opinions on current clinical trial data and application to practice. The panel will review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world treatment, and compare their practices with those of other experts in the field, and peers, as a vehicle that enhances learning of key emerging treatment concepts. This panel discussion will be filmed and endured online in PER’s legacy Medical Crossfire® multi-module format, available on www.gotoper.com.
Instructions For This Activity & Receiving Credit
This activity is intended for medical oncologists, nurses, pathologists, pulmonologists, interventional radiologists, thoracic surgeons, and other health-care professionals involved in the care of patients with advanced NSCLC may also participate.
Naiyer Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics Price
Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY
Disclosure: Consultant: AstraZeneca, Roche, Novartis, and Merck; Stock/Shareholder: Gritstone Oncology
Edward Garon, MD
Hematology & Oncology
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA
Disclosure: Grant/Research Support: AstraZeneca, Merck, BMS, Eli Lily, Pfizer, Novartis, and Genentech (related to clinical trials)
Leena Gandhi, MD
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Disclosure: Grant/Research Support: BMS; Consultant: Scientific Advisory Board- Merck, AbbVie, Pfizer, Astra-Zeneca, Genentech/Roche; Other Support (Honoraria): Merck
Roy Herbst, MD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosure: Scientific Advisory Board: Biothera, Diatech, and Koltan; Consulting: AstraZeneca, Eli Lily, Genentech/Roche, Merck, and Pfizer; Clinical Trials Support/Grant: Genentech, and Merck
The following individuals have no relevant financial relationships with commercial interests:
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Feb 10, 2018
February 10, 2018
New York, NY
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Feb 28, 2018
Feb 28, 2018
Feb 28, 2018